Pharmacokinetic variability and complex two‐way interactions with cenobamate in patients with refractory epilepsy
Epilepsia · 2026
DOI: 10.1002/epi.70184 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsia, 2026. Verfasst von Cecilie Johannessen Landmark und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Resistant Epilepsy, Carbamates, Tetrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objectives
Cenobamate (CNB) is a new antiseizure medication (ASM) for add‐on therapy in adults with refractory epilepsy. The purpose of this study was to investigate the pharmacokinetic variability of CNB and extent of interactions with other ASMs.
Methods
In this observational therapeutic drug monitoring (TDM) study we included all patients with serum concentrations of CNB and concomitantly used ASMs (2022–2025) from the Section for Clinical Pharmacology, National Center for Epilepsy, Oslo University Hospital.
Results
Data from 258 patients included 672 serum CNB concentration measurements (1–7 per patient; 56% women; median age = 36 years, range = 11–77). Mean daily dose and serum concentration at the most recent measurement were 164 mg/day (range = 12.5–400, SD = 88.6) and 53.7 μmol L −1 (range 5–186, SD = 34.8). Intraindividual variation in CNB concentration/dose (C/D) ratios ranged from 6% to 33% (coefficient of variation = 18%); interpatient variability was 34‐fold. Comedication was a contributing but variable factor. Mean CNB C/D ratios were affected by strong enzyme inducers (−9%) and inhibitors (+14%) as compared to neutral ASMs ( p < .05). Twenty‐four concomitant ASMs were used (1–6 per patient, mean = 1.91, SD = .94); clobazam, lamotrigine, and valproate were the most common. After initiating CNB, significant but variable increases in mean C/D ratios of desmethylclobazam (+233%, and +344% for the Cd‐clb/Cclb€ ratio, n = 57) and phenobarbital (+36%, n = 15) were observed, as were decreases for lamotrigine (−28%, n = 57) and carbamazepine (−26%, n = 7) ( p < .05). For most other ASMs, there were unpredictable changes in individual C/D ratios. Significance We demonstrate complex and unpredictable two‐way interactions in polytherapy with CNB and pronounced pharmacokinetic variability among patients with refractory epilepsy, elucidating the usefulness of TDM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
- Section for Clinical Pharmacology, National Center for Epilepsy, Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
- National Center for Epilepsy, Oslo University Hospital, Full member of the ERN EpiCare, Sandvika, Norway.
- Lillehammer Trust Hospital, Lillehammer, Norway.
ORCID-Profile: Cecilie Johannessen Landmark
Zitieren
APA
Johannessen Landmark, C., Belkilani, H., Awad, L., Burns, M. L., Gottås, A., Svendsen, T., & Sætre, E. (2026). Pharmacokinetic variability and complex two‐way interactions with cenobamate in patients with refractory epilepsy. Epilepsia. https://doi.org/10.1002/epi.70184
Vancouver
Johannessen Landmark C, Belkilani H, Awad L, Burns ML, Gottås A, Svendsen T, et al. Pharmacokinetic variability and complex two‐way interactions with cenobamate in patients with refractory epilepsy. Epilepsia. 2026. doi:10.1002/epi.70184
BibTeX
@article{JohannessenLandmark2026,
author = {Johannessen Landmark, Cecilie and Belkilani, Heba and Awad, Lilyana and Burns, Margrete Larsen and Gottås, André and Svendsen, Torleiv and Sætre, Erik},
title = {Pharmacokinetic variability and complex two‐way interactions with cenobamate in patients with refractory epilepsy},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70184}
}
EUVIMED